CapsoVision (NASDAQ:CV) Major Shareholder Eliyahou Et Al Harari Buys 13,850 Shares

CapsoVision, Inc. (NASDAQ:CV) major shareholder Eliyahou Et Al Harari purchased 13,850 shares of the stock in a transaction dated Friday, June 26th. The stock was purchased at an average cost of $7.35 per share, for a total transaction of $101,797.50. Following the completion of the purchase, the insider directly owned 3,200,751 shares of the company’s stock, valued at approximately $23,525,519.85. The trade was a 0.43% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

CapsoVision Stock Up 8.1%

Shares of NASDAQ CV opened at $6.13 on Thursday. The firm has a 50-day simple moving average of $6.89 and a 200-day simple moving average of $6.76. The stock has a market capitalization of $306.25 million and a price-to-earnings ratio of -2.62. CapsoVision, Inc. has a 52 week low of $3.43 and a 52 week high of $15.37.

CapsoVision (NASDAQ:CV) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.15) EPS for the quarter. The company had revenue of $2.79 million during the quarter.

Wall Street Analyst Weigh In

A number of research firms have commented on CV. Benchmark decreased their target price on shares of CapsoVision from $14.00 to $10.00 and set a “speculative buy” rating on the stock in a research report on Friday, March 27th. Weiss Ratings restated a “sell (d-)” rating on shares of CapsoVision in a research note on Monday, June 29th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $8.50.

Institutional Investors Weigh In On CapsoVision

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Wells Fargo & Company MN grew its stake in shares of CapsoVision by 66.4% during the fourth quarter. Wells Fargo & Company MN now owns 6,287 shares of the company’s stock worth $67,000 after purchasing an additional 2,508 shares in the last quarter. Deutsche Bank AG acquired a new stake in CapsoVision in the fourth quarter valued at $47,000. Virtu Financial LLC acquired a new stake in CapsoVision in the fourth quarter valued at $128,000. Millennium Management LLC purchased a new stake in CapsoVision during the 4th quarter worth about $163,000. Finally, Bank of America Corp DE lifted its holdings in CapsoVision by 528.9% during the 1st quarter. Bank of America Corp DE now owns 22,238 shares of the company’s stock worth $162,000 after buying an additional 18,702 shares during the last quarter.

CapsoVision Company Profile

CapsoVision, Inc (NASDAQ: CV) is a medical device company specializing in advanced capsule endoscopy systems for gastrointestinal diagnostics. The company’s flagship product, the CapsoCam® Plus System, features a swallowable, tether-free capsule equipped with four side-viewing cameras that capture high-resolution, 360-degree images of the small intestine. By storing images internally rather than transmitting data wirelessly, CapsoCam Plus enables patients to maintain normal daily activities during the procedure and reduces the risk of signal loss or image drop-out.

In addition to its capsule hardware, CapsoVision offers CapsoCloud®, a secure, cloud-based platform that streamlines image retrieval, storage and reporting.